568591-39-9

Upstream product

• 3779-29-1 diethyl cyclobutane-1,1-dicarboxylate 
• 4415-73-0 [1-(hydroxymethyl)cyclobutyl]methanol 
• 100-39-0 benzyl bromide 

Downstream Products

• 568591-40-2 {1-[(benzyloxy)methyl]cyclobutyl}methanol methanesulfonate 
• 927835-84-5 ((1-(benzyloxymethyl)cyclobutyl)methoxy)benzene 
• 1333467-15-4 N-{4-(1-benzyloxymethylcyclobutyl)-4-hydroxy-2-butynyl}-N-(2-propynyl)-4-methylbenzenesulfonamide 
• 1333467-27-8 1-[(benzyloxy)methyl]cyclobutane-1-carbaldehyde 
• 1333466-99-1 N-{4-(1-benzyloxymethylcyclobutyl)-2-phenylsulfonyl-2,3-butadienyl}-N-(2-propynyl)-4-methylbenzenesulfonamide 
• 1221503-76-9 1-({1-[(benzyloxy)methyl]cyclobutyl}methyl)-4-bromo-5-(4-fluorophenyl)-3-methyl-1H-pyrazole 
• 568591-79-7 {1-[(4-trifluoromethyl-1,3-thiazol-2-yl)methyl]cyclobutyl}methyl (1S)-1-(1-hydroxy-2-oxo-2-{[(1R)-1-phenylethyl]amino}ethyl)pentylcarbamate 
• 568591-45-7 {1-[(4-phenyl-1,3-thiazol-2-yl)methyl]cyclobutyl}methyl (1S)-1-(1-hydroxy-2-oxo-2-{[(1R)-1-phenylethyl]amino}ethyl)pentylcarbamate 
• 849693-16-9 2-(1-benzyloxymethyl-cyclobutylmethyl)-4-trifluoromethyl-thiazole 
• 568591-44-6 {1-[(4-phenyl-1,3-thiazol-2-yl)methyl]cyclobutyl}methanol 
• 568591-42-4 2-{1-[(benzyloxy)methyl]cyclobutyl}ethanethioamide 
• 568591-41-3 {1-[(benzyloxy)methyl]cyclobutyl}acetonitrile 
• 1310807-78-3 methyl 3-({1-[(benzyloxy)methyl]cyclobutyl}methoxy)-5-(4-nitrophenoxy)benzoate 

Relevant academic research and scientific papers

SUBSTITUTED TRICYCLICS AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications

Osteoporosis is a disease characterized by skeletal fragility. Cathepsin K, a lysosomal cysteine protease, has been implicated in the osteoclast mediated bone resorption. Inhibitors of this protease could potentially treat this skeletal disease. The prese